Kinase inhibition continues to be a major focus of pharmaceutical research and discovery due to the central role of these proteins in the regulation of cellular processes. One family of kinases of pharmacological interest, due to its role in activation of immunostimulatory pathways, is the Janus kinase family. Small molecule inhibitors targeting the individual kinase proteins within this family have long been sought-after therapies. High sequence and structural similarity of the family members makes selective inhibitors difficult to identify but critical because of their inter-related multiple cellular regulatory pathways. Herein, we describe the identification of inhibitors of the important Janus kinase, TYK2, a regulator of type I interferon response. In addition, the biochemical and structural confirmation of the direct interaction of these small molecules with the TYK2 pseudokinase domain is described and a potential mechanism of allosteric regulation of TYK2 activity through stabilization of the pseudokinase domain is proposed.
Keywords: Crystallization; Deucravacitinib; HTRF probe; ITC; Isothermal titration calorimetry; Janus kinase family; Pseudokinases; TSA; TYK2; TYK2-JH2; TYK2-JH2 PSEUDOKINASE DOMAIN BINDERS; Thermal shift assay.
Copyright © 2022 Elsevier Inc. All rights reserved.